期刊
JOURNAL OF NEUROCHEMISTRY
卷 139, 期 -, 页码 75-76出版社
WILEY-BLACKWELL
DOI: 10.1111/jnc.13549
关键词
-
资金
- NINDS NIH HHS [P50 NS038377] Funding Source: Medline
A common cause of Parkinson disease are missense mutations in the leucine-rich repeat kinase 2 (LRRK2) catalytic Roc-COR domain, leading to a decrease in GTPase activity; and its kinase domain, leading to an increase in kinase activity and subsequent LRRK2 toxicity. Targeting LRRK2 with selective, brain-permeable kinase inhibitors is a promising approach to reduce toxicity, and thus is a major goal of clinical development. Understanding the specific signaling cascades triggered by LRRK2 mutations will be key to this aim. This article is part of a . This article is part of a .
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据